News & Insights
Bausch + Lomb CEO: the AI hysteria is nothing new
The AI arms race will be won by the companies whose people keep learning what to do with it, Brent writes for Fortune.
The Real Difference in the AI Era
Brent shares his perspective on AI leadership and organizational culture with Alan Murray for the Wall Street Journal CEO Brief.
Exclusive: Brent Saunders’ latest dermatology bet gets $20M for skin longevity
In an Endpoints News exclusive, Brent shares the premise behind Rapalogix health and the company’s plans to change how we think about skin health.
AI could take ‘years’ off the drug development process, says Bausch + Lomb CEO Brent Saunders
Brent joined “Squawk on the Street” to discuss the impacts of artificial intelligence on health care, Bausch + Lomb’s latest earnings report, and more.
Bausch + Lomb CEO: Standing still is the new falling behind
In a piece for Fortune, Brent covers the AI upskilling imperative and why he we made AI training mandatory for 8,000+ employees at Bausch + Lomb.
Brent Saunders: Eyeing New Horizons
Pharmaceutical Executive highlights Bausch + Lomb’s transformation under Brent, with a focus on the company’s rebuilt pipeline.
Bausch + Lomb CEO: the AI hysteria is nothing new
The AI arms race will be won by the companies whose people keep learning what to do with it, Brent writes for Fortune.
The Real Difference in the AI Era
Brent shares his perspective on AI leadership and organizational culture with Alan Murray for the Wall Street Journal CEO Brief.
Exclusive: Brent Saunders’ latest dermatology bet gets $20M for skin longevity
In an Endpoints News exclusive, Brent shares the premise behind Rapalogix health and the company’s plans to change how we think about skin health.
AI could take ‘years’ off the drug development process, says Bausch + Lomb CEO Brent Saunders
Brent joined “Squawk on the Street” to discuss the impacts of artificial intelligence on health care, Bausch + Lomb’s latest earnings report, and more.